Exicure agrees to sell GPC-100 program assets to GPCRT Inc. for KRW 6.5 billion
The Delaware biotech will transfer rights tied to its burixafor program to the Korean buyer in a cash deal worth about $4.8 million.
Exicure, Inc. announced on November 10, 2026 that it and its wholly owned subsidiary, GPCR Therapeutics USA Inc., signed an Intellectual Property, Asset and License Assignment Agreement on November 4, 2026 with GPCRT Inc., a company organized under the laws of the Republic of Korea.1 Under the agreement, GPCRT will acquire the GPC-100 (burixafor) program assets for a total cash price of KRW 6.5 billion, or roughly $4.8 million.1
The assets being transferred include Exicure's rights under its January 19, 2025 License and Collaboration Agreement with GPCR Therapeutics, Inc., along with related contracts, intellectual property, and clinical and regulatory data tied to the GPC-100 program.1 The program itself involves testing burixafor paired with propranolol as a way to mobilize stem cells in multiple myeloma patients, and GPCR USA finished a Phase 2 trial of GPC-100 in January 2026.1 GPCR USA itself will stay a wholly owned Exicure subsidiary once the sale closes.1
Payment is structured in three parts. GPCRT already paid a KRW 500 million deposit that counts against the total price, owes an interim KRW 2 billion payment by November 16, 2026, and will pay the final KRW 4 billion installment at closing, unless the parties agree to different dates in writing.1 Once the deal closes, GPCRT will take on the ongoing obligations under the license agreement, including future milestones and royalties, and will cover GPC-100 program costs starting September 1, 2026,1 while Exicure and GPCR USA keep responsibility for liabilities incurred before that date.1
Closing still depends on standard conditions such as regulatory approvals, third-party consents, a waiver from GPCR Therapeutics, Inc., and possible stockholder approval.1 The company cautioned that there is no guarantee the transaction closes on the expected schedule or at all.1 Exicure described the sale as part of its continuing review of strategic alternatives meant to strengthen its financial position.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.